Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies

US11001636B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Anne-Sophie REBSTOCK · Écully, FR
• Yolanda Cancho Grande · Leverkusen, DE
• Sven Wittrock · Berlin, DE
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Dennis KIRCHHOFF · Berlin, DE
• Christoph MAHLERT · Wuppertal, DE
• Simone Greven · Dormagen, DE
• Stephan MÄRSCH · Cologne, DE

Key dates

• Filing date: Jun 8, 2017
• Grant date: May 11, 2021
• Expiry date: Nov 8, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.